文献速递乳房整形与再造

TiLOOP® Bra 乳房再造:整形外科医生箭袋中的又一支箭?

Breast reconstruction with TiLOOP® Bra: Another arrow in plastic surgeons' quiver?
PubMed 文献 · J Plast Reconstr Aesthet Surg · 2024-07-29

该系统综述通过检索三个数据库,最终纳入41篇文献、共3923例患者和5042个再造乳房,评估TiLOOP® Bra在乳房再造中的并发症与患者报告结局。作者认为,在非吸烟、接受保留皮肤乳头或减容乳房切除并即刻再造的患者中,TiLOOP® Bra可视为脱细胞真皮基质的安全且美学有效的替代选择。

要点

  • TiLOOP® Bra在非吸烟的保留皮肤乳头或减容乳房切除即刻再造患者中,可考虑作为脱细胞真皮基质的安全且美学有效替代。
  • TiLOOP® Bra的血清肿发生率与脱细胞真皮基质相当,在放疗患者中TiLOOP® Bra似乎优于单纯假体再造。
  • 极端体重指数患者更易发生并发症,TiLOOP® Bra与宿主组织生物整合良好并对免疫减弱患者有抗感染能力。

核心结论

  • 在非吸烟、接受保留皮肤乳头或减容乳房切除并即刻再造的患者中,TiLOOP® Bra可考虑作为脱细胞真皮基质的安全且美学有效的替代选择。
  • 此类人群中,极端体重指数患者更易发生并发症;TiLOOP® Bra的血清肿发生率与脱细胞真皮基质相当,在放疗患者中TiLOOP® Bra似乎优于单纯假体再造。
  • TiLOOP® Bra与宿主组织生物整合良好,并对因肿瘤围手术期治疗导致免疫减弱的患者具有抗感染能力。

研究设计与样本

  • 系统文献综述,检索PubMed、Web of Sciences和Embase三个数据库,关键词为「breast reconstruction」AND「TiLOOP®」OR「Titanium-Coated Polypropylene Mesh」OR「TCPM」。
  • 初检234篇文献,最终纳入41篇,共3923例患者和5042个再造乳房。
  • 评估内容包括患者围手术期与人口学特征、并发症谱及患者报告结局。

主要发现

  • 共纳入41篇文献,包括3923例患者和5042个再造乳房。
  • TiLOOP® Bra的血清肿发生率与脱细胞真皮基质相当。
  • 在放疗患者中,TiLOOP® Bra似乎优于单纯假体再造。
  • 极端体重指数患者更易发生并发症。
  • TiLOOP® Bra与宿主组织生物整合良好,并对免疫减弱患者具有抗感染能力。

临床怎么用

  • 作者认为,在非吸烟、接受保留皮肤乳头或减容乳房切除并即刻再造的患者中,TiLOOP® Bra可考虑作为脱细胞真皮基质的安全且美学有效的替代选择。
  • 作者指出,此类人群中极端体重指数患者更易发生并发症。
  • 作者指出,TiLOOP® Bra的血清肿发生率与脱细胞真皮基质相当,在放疗患者中TiLOOP® Bra似乎优于单纯假体再造。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of lower-pole sling products has made immediate breast reconstruction a feasible option in women undergoing skin-nipple sparing and skin-reducing mastectomies. To date, available data on the comparative efficacy of biological and synthetic meshes regarding postoperative complications are scattered and limited. METHODS: A systematic literature search was performed to screen three different databases (PubMed, Web of Sciences, and Embase) using the following keywords: "breast reconstruction" AND "TiLOOP®" OR "Titanium-Coated Polypropylene Mesh" OR "TCPM". The perioperative and demographic characteristics of patients, complications profiles, and patient-reported outcomes were considered. RESULTS: We initially identified 234 articles, of which only 41, including 3923 patients and 5042 reconstructed breasts, fully satisfied the inclusion criteria. CONCLUSION: TiLOOP® Bra could be considered a safe and aesthetically valid alternative to Acellular Dermal Matrices (ADMs) in non-smokers patients undergoing skin-nipple sparing and skin-reducing mastectomies and immediate reconstruction. In such populations, complications are more likely to develop in patients with extreme body mass index values. The incidence of seroma with TiLOOP® Bra is comparable to that of ADMs as it is the beneficial effect in radiated patients, where TiLOOP® Bra seems superior to implant alone reconstruction. It has a good bio-integration with host tissues and resistance to infections in patients with a weakened immune system as a consequence of oncologic perioperative treatments.

来源:J Plast Reconstr Aesthet Surg,查看原文。版权归原作者所有。

引用

  1. Tellarini A, Bascialla E, Paganini F, et al. Breast reconstruction with TiLOOP® Bra: Another arrow in plastic surgeons' quiver? J Plast Reconstr Aesthet Surg. 2024. PMID: 39151289. doi:10.1016/j.bjps.2024.07.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。